RDHL RedHill Biopharma Ltd.
Healthcare$1.01+3.08%ClosedMarket Cap: $3.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.41
P/S
0.45
EV/EBITDA
-0.03
DCF Value
$-0.11
FCF Yield
-214.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.3%
Operating Margin
-109.5%
Net Margin
-98.7%
ROE
291.1%
ROA
-26.5%
ROIC
-118.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY null | $286.0K | 100.0% | $-7.9M | $-429.0K | $— | — |
| Q2 null | $2.0M | 60.6% | $-2.2M | $-2.1M | $— | — |
| Q1 null | $2.0M | 60.6% | $-2.2M | $-2.1M | $— | — |
| Q4 null | $2.7M | 67.3% | $-3.1M | $-2.6M | $— | — |
| FY null | $8.0M | 60.3% | $-14.6M | $-8.3M | $— | — |
| Q3 null | $2.7M | 67.3% | $-3.1M | $-2.6M | $— | — |
| Q2 null | $1.3M | 45.4% | $-4.2M | $-1.5M | $— | — |
| Q1 null | $1.3M | 45.4% | $-4.2M | $-1.5M | $— | — |
| Q4 null | $567.5K | 8.3% | $-6.0M | $-13.5M | $— | — |
| FY null | $6.5M | 47.0% | $12.6M | $23.9M | $— | — |
| Q3 null | $567.5K | 8.3% | $-6.0M | $-13.5M | $— | — |
| Q2 2023 | $1.8M | 55.1% | $-4.4M | $761.0K | $3.00 | — |